DC Federal Court in the US has not granted Ranbaxy Laboratories' temporary restraining order to block the US health regulator from approving other ANDAs for generic versions of digestive disorder medicine Nexium and anti-viral Valcyte. However, the court ordered the parties to the suit to agree upon a schedule for filing additional legal briefs, addressing Ranbaxy’s request for a preliminary injunction by November 21, 2014. Earlier, the company had filed a complaint against the US FDA in D.C. Federal Court and had also asked the Court for a temporary restraining order to prevent any further action by FDA until Ranbaxy's case is decided.
Ranbaxy Laboratories is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1660.35 |
| Dr. Reddys Lab | 1220.80 |
| Cipla | 1236.00 |
| Zydus Lifesciences | 928.80 |
| Lupin | 2313.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: